Generalisierte pustulöse Psoriasis: Ein IL-36-Rezeptor Antikörper zeigt großes Potenzial

Generalized pustular psoriasis is a potentially life-threatening neutrophilic skin disease characterized by recurrent flares of widespread erythema and eruption sterile pustules. In the Effisayil™ 1 study (NCT03782792), 53 patients with generalized flare were treated placebo or spesolimab, humanized anti-interleukin-36 receptor monoclonal antibody, first targeted treatment to be studied in randomized clinical trial. Spesolimab resulted rapid clearance, an acceptable safety profile. Here, we evaluate efficacy spesolimab 29 Asian study. The primary endpoint, Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore 0 (no visible pustules) at Week 1, was achieved 10 (62.5%) one patient (7.7%) (risk difference 54.8, 95% confidence interval [CI] 17.3-79.8). key secondary GPPGA total score (clear almost clear skin) eight (50.0%) two (15.4%) patients, respectively 34.6, CI -3.1-64.7). This similar previously published data overall population whom endpoints 54% versus 6% 43% 11% respectively. percentages sustained above 60% for up 12 weeks. these patient-reported outcomes also improved markers systemic inflammation normalized. Eleven (68.8%) (61.5%) spesolimab- placebo-treated respectively, experienced least adverse event. conclusion, compared placebo, supporting its use flares.